Pharmaceutical compositions for treating arrhythmia and therapeutics of
A pharmaceutical composition and technology for arrhythmia, applied in the field of pharmaceutical composition for treating arrhythmia
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0031] method
[0032] Chemical material
[0033] BP (A10353) was purchased from Alfa Aesar. Dissolve BP in dimethyl sulfoxide (DMSO; Sigma), shake at 25°C for 1 hour, and store at 4°C for later use.
[0034] Isolation of human ADSCs
[0035] In this example, the 3-5 generations of ADSCs were used (approved by the China Medical University Experimental Ethics Committee, provided by Guoxi Stem Cell Application Technology Co., Ltd. (Hsinchu, Taiwan)). These ADSCs are identical and do not contain endothelial cells or hematopoietic lineages. Cultured ADSCs have a mesenchymal stem cell phenotype: express the mesenchymal stem cell marker CD90, and will not express the hematopoietic markers CD31 and CD34. The cell characteristics are approved by the competent authority in Taiwan. In addition, hADSCs have been used in clinical trials of liver cirrhosis.
[0036] The cells were placed in cells containing 10% (v / v) FBS (fetal bovine serum), 10ng / ml bFGF (basic fibroblast growth factor, R&D Sy...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


